Ceragennins show in vitro angiogenesis activity
Ceragenix Pharmaceuticals, a US biopharmaceutical company focused on infectious diseases and dermatology, says that data received from the National Cancer Institute showed that two of its drug candidates inhibit angiogenesis at low micromolar concentrations.
Both compounds are Ceragenins (CSAs), a class of synthetically-produced small-molecules originated by the firm which consist of a sterol backbone with amino acids and other groups attached to them,
According to Ceragenix, three in vitro models were used - a growth inhibition assay, a cord formation assay and a cell migration assay - and the lowest reported inhibitory concentration for one of its Ceragenins was 4.49 micromoles.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze